The Efficiency of the EORTC Scoring System for the Prediction of Recurrence and Progression of Non-muscle-invasive Bladder Cancer Treated by Bacillus Calmette-Guerin Immunotherapy

Abstract

The authors determined the recurrence and progression at 1 year in patients with non-muscle-invasive urothelial carcinoma who underwent transurethral resection of bladder tumor (TURBT) and compared the results with the calculated risk according to the European Organization of Research and Treatment of Cancer (EORTC). Between 2002 and 2011, a total of 112 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the EORTC scoring system, the patients were categorized in terms of number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and pathologic grade, and the scores were summed. According to the summed scores, the recurrence group and the progression group were divided into 3 subgroups: low, intermediate, and high risk, respectively. The recurrence rate and progression rate of each group were compared with the EORTC risk tables. The mean patient age was 63.9 years (range: 25-85) at diagnosis. Seventy-eight patients (68.4%) had a recurrent disease, 53 (47.3%) had a tumor larger than 3 cm in diameter, 55 (49.1%) had multiple lesions, 3 (0.26%) had carcinoma in situ, 44(39.3%) had stage T1 lesions, and 20 (17.8%) had a high-grade disease. The recurrence rates were 0, 14.2, 31.25, and 85.71% in groups with the predicted EORTC risks of 15, 24, 38, and 61%, respectively. There were 3 patients (0.2%) with progression of the diseases. The EORTC model successfully stratified recurrence and progression risks in this cohort. However, the discriminative ability of the EORTC tables decreased in these patients for progression.

Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor‐β‐induced expression in urothelial carcinoma

“…Although some attempts have been made to predict the recurrence of UC, the mechanisms underlying recurrence and progression remain obscure . TGFBI is a multi‐functional protein that commonly exists in normal as well as tumor cells.…”

Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma

“…Attempts have been made to predict recurrences in patients with TCCs; however, the mechanism underlying recurrence remains obscure (32)(33)(34). Since FLOT1 acts as an important gene in various biological behaviors, such as cell adhesion and invasion, a study suggested that FLOT1 can enhance cell invasion by increasing NF-κB activation in esophageal squamous cell carcinoma cells (22).…”

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1

“…Seo et al ( 18 ) validated the risk Tables, since identified a recurrence rate similar to Sylvester et al ( 4 ). Ajili et al ( 19 ) and Ather and Zaidi ( 20 ) identified significant correlation for recurrence in 1 year with the Sylvester et al study ( 4 ). Altieri et al ( 21 ) identified a recurrence rate similar to those of EORTC Tables and confirmed their use essential to daily practice.…”